Compare · BJDX vs MDLN
BJDX vs MDLN
Side-by-side comparison of Bluejay Diagnostics Inc. (BJDX) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BJDX and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 13808.0x BJDX ($3.5M).
- MDLN has been more active in the news (7 items in the past 4 weeks vs 4 for BJDX).
- MDLN has more recent analyst coverage (25 ratings vs 1 for BJDX).
- Company
- Bluejay Diagnostics Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $3.5M
- $48.08B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2025
- News (4w)
- 4
- 7
- Recent ratings
- 1
- 25
Bluejay Diagnostics Inc.
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Latest BJDX
- SEC Form 8-K filed by Bluejay Diagnostics Inc.
- Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
- SEC Form 8-K filed by Bluejay Diagnostics Inc.
- Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock
- Bluejay Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
- President and CEO Dey Indranil was granted 28,000 shares, increasing direct ownership by 224% to 40,522 units (SEC Form 4)
- SEC Form 4 filed by Director Dey Svetlana
- SEC Form 4 filed by Director Wurth Douglas Clark
- SEC Form 4 filed by Director Zeidman Fred S
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M